Vaxxas raises $34 million for clinical program, increased output
Needle-free vaccination company Vaxxas has announced completion of a funding round worth $34 million, which it says will help it build production capacity and accelerate its clinical program for a Covid-19 vaccine candidate. Among existing investors in the round were OneVentures and University of Queensland technology transfer organisation Uniquest. “This financing from a strong syndicate…
Details